Karyopharm Therapeutics Inc [KPTI] stock is trading at $0.90, down -8.75%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KPTI shares have gain 9.20% over the last week, with a monthly amount glided 2.52%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock has seen the most recent analyst activity on January 19, 2023, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $8. Previously, RBC Capital Mkts upgraded its rating to Outperform on November 04, 2022, and elevated its price target to $10. On February 09, 2022, upgrade upgraded it’s rating to Neutral but maintained its price target of $8 on the stock. SVB Leerink downgraded its rating to a Mkt Perform but $6 remained the price target by the analyst firm on August 06, 2021. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 06, 2021, and downed its price target to $8. In a note dated August 06, 2021, JP Morgan downgraded an Neutral rating on this stock.
Karyopharm Therapeutics Inc [KPTI] stock has fluctuated between $0.62 and $1.95 over the past year. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Karyopharm Therapeutics Inc [NASDAQ: KPTI] shares were valued at $0.90 at the most recent close of the market. An investor can expect a potential return of 714.44% based on the average KPTI price forecast.
Analyzing the KPTI fundamentals
Karyopharm Therapeutics Inc [NASDAQ:KPTI] reported sales of 145.67M for the trailing twelve months, which represents a growth of 13.86%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.9%, Pretax Profit Margin comes in at -0.62%, and Net Profit Margin reading is -0.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is 0.67 and Total Capital is -0.84. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8491 points at the first support level, and at 0.7949 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9887, and for the 2nd resistance point, it is at 1.0741.
Ratios To Look Out For
For context, Karyopharm Therapeutics Inc’s Current Ratio is 3.62. Also, the Quick Ratio is 3.56, while the Cash Ratio stands at 1.47. Considering the valuation of this stock, the price to sales ratio is 0.71.
Transactions by insiders
Recent insider trading involved Paulson Richard A., President and CEO, that happened on Oct 04 ’24 when 3607.0 shares were sold. SVP, General Counsel&Secretary, Mano Michael completed a deal on Sep 04 ’24 to sell 3971.0 shares. Meanwhile, President and CEO Paulson Richard A. sold 3667.0 shares on Sep 04 ’24.
